Hepatect

Hepatect is a solution for injection containing Human Hepatitis B Immunoglobulin as the active ingredient. It is supplied in an unspecified strength and is marketed in the European Union as a prescription‑only immunoglobulin product for passive immunity against hepatitis B virus.

Hepatect is indicated for specific clinical situations where passive hepatitis B immunity is required.

- Prevention of hepatitis B infection after known or suspected exposure to hepatitis B virus. - Prophylaxis of hepatitis B recurrence in patients undergoing liver transplantation. - Supplementation of hepatitis B immune globulin in individuals with inadequate vaccine response. - Use in combination with hepatitis B vaccine for enhanced protection in high‑risk settings. - Administration to newborns of hepatitis B‑positive mothers to prevent perinatal transmission.

Side effects of Hepatect may vary in frequency and severity.

Common: - Mild fever or chills during or after infusion. - Localized pain, redness, or swelling at the injection site. - Headache or fatigue. - Nausea or mild gastrointestinal discomfort. - Transient elevation of liver enzymes.

Serious: - Severe allergic reaction (anaphylaxis) with rash, wheezing, or hypotension. - Acute hemolysis or hemolytic anemia. - Renal impairment or acute kidney injury. - Thromboembolic events such as deep vein thrombosis. - Severe thrombocytopenia or bleeding disorders.

When prescribing or administering Hepatect, several precautions should be observed.

- Assess patient history for prior hypersensitivity to human immunoglobulins or blood products. - Monitor vital signs and for signs of anaphylaxis during the initial infusion. - Use caution in patients with renal insufficiency; adjust infusion rate as needed. - Evaluate liver function tests before and after administration, especially in transplant recipients. - Avoid use in individuals with known IgA deficiency who have anti‑IgA antibodies. - Document hepatitis B surface antigen status and prior vaccination history. - Ensure proper aseptic technique to prevent contamination of the injectable solution.

Hepatect may interact with other medications or clinical conditions.

Avoid: - Concurrent administration of other blood‑derived products without appropriate monitoring. - Use with live attenuated vaccines during the same infusion period.

Use with caution: - Immunosuppressive agents (e.g., corticosteroids, calcineurin inhibitors) as they may alter immune response. - Anticoagulants, because infusion may affect coagulation parameters. - Nephrotoxic drugs, given potential renal effects. - Hepatotoxic medications, due to overlapping liver safety concerns. - Agents that may cause hypersensitivity reactions, requiring close observation.